Heat Failure Drugs
Heat Failure Drugs
Heat Failure Drugs
PHAM/MG/1991/09/19
Heart failure occurs when cardiac output is inadequate to provide required oxygen by the body oftenly
punctuated with cases of acute decompensation that requires hospitalisation in many cases.
Treatment is therefore is based on these main goals:(1) Reduction of symptoms and slowing progression
as much as possible during relatively stable periods and (2) managing acute episodes of decompesated
failure.
1. Diuretics
2. Aldosterone receptor blockers
3. Angiotensin converting enzyme inhibitors
4. Beta blockers
5. Cardiac glycosides
6. Vasodilators
7. Beta agonists
8. Bipyridines
9. Natriuretic peptides
Diuretics
The main action mechanism of these drug class in heart failure is through reduction of venous pressure
and ventricular preload.
The effects of these action causes increased salt and water excretion,reduced cardiac preload and
afterload and reduction in pulmonary and peripheral edema .
Thus,these drugs can be used in acute and chronic heart failure patients.
Drug-drug interactions
Dosage
Furosemide -20mg
Torsemide - 10mg
Bumetanide - 0.5 mg
✓Hence, they have similar effects as seen in loop diuretics though less efficacious
✓Clinically, they have been utilised for mild chronic heart failure.
✓other clinical utilisations include hypercalciuria treatment and mild - moderate hypertension.
1.Hyponatremia
2.Hypokalemia
3.Hyperglycemia
4.Hyperuricemia
5.Hyperlipidemia
6.Sulfonamide allergy
These work by causing blocking aldosterone receptors in the collecting tubules of nephron thus leading
to increased salt and water excretion and a reduction in cardiac remodeling.
Clinical application
✓aldosteronism
✓Hypertension
Side effects
1. Hyperkalemia
2. Spirinolactone exhibits gynecomastia
These offer Beta 1 receptor blockade competitively thus lead to a reduction in heart rate and blood
pressure.
Clinical application
In chronic heart failure to slow progression and in moderate to severe heart failure.
Side effects
✓bradycardia
✓AV block
✓Bronchospasm
These act by causing Na+/K+ -ATPase resulting in reduction in Ca2+ stored in sarcoplasmic reticulum.
Thus these leads to increased cardiac contractility
However,they have cardiac parasympathomimetic effects like slowed heart rate and slowed Av
conduction.
Clinical applications
Toxicities of digoxin
Interactions of Digoxin
Area under the curve is increase by 16% by Eplerenone
St Johns wort reduces digoxin levels
Clarythromycin increases digoxin levels and may lead to digoxin toxicity.
Vasodilators
These,cause release of Nitric oxide activating guanyl cyclase thus promoting venodilation , and
reducing preload and ventricular stretch.
Clinical applications
Toxicities
1. Postural hypotension
2. Tachycardia
3. Headache
Increases Nitric oxide synthesis in the endothelium;and its effects is a reduction in blood pressure and
afterload; besides increasing cardiac output.
Clinical application
Hydralazine reduces mortality rates of heart failure when used with organic nitrates.
Side effects
1. Tachycardia
2. Fluid like retention
3. Lupus like syndrome
These increase Nitric oxide synthesis causing a reduction in blood pressure and preload and after load.
Clinical applications
1. Hypotension
2. Thiocyanate and cyanide toxicities
Beta adrenoceptors
Clinical application
Side effects
1. Arrhythmias
Interactions
2.Dopamine
These activates dopamine receptors and at higher doses beta and alpha adrenoceptors.
Dopamine has the effects of increasing renal blood flow and at higher dose increasing cardiac force and
blood pressure.
Clinical applications
Toxicities
Arrhythmias
Bipyridines eg Milrinone
The drug is a phosphodiesterase type3 inhibitor that causes a increase in cAMp levels by inhibiting its
break down.
It has a net effect of causing vasodilation thus reducing peripheral vascular resistance and also plays role
in increase in cardiac contractility.
Clinical applications
Toxicities
✓Arrhythmias
Interactions
Clinical applications
Toxicities
Renal damage
Hypotension
Other drugs
1. K.G.,Betram,T.J.,Trevor, (2012), Basic and Clinical Pharmacology,13th Edition,Mc Graw Hill Education,
(pp 209-219).